Technology Bundle ID
TAB-2854
Inhibition of HIV Infection through Chemoprophylaxis Using Emtricitabine and Tenofovir
Linked ID
E-195-2013-0
Lead Inventors
Walid Heneine (CDC)
Co-Inventors
Jose Garcia Lerma (CDC)
Robert Janssen (CDC)
Ronald Otten (CDC)
Thomas Folks (CDC)
Development Stages
Pre-clinical (in vivo)
Development Status
- In vivo data available (animal)
- In vivo data available (human)
ICs
CDC
The invention is directed to prophylactic administration of emtricitabine (FTC) in combination with tenofovir or its prodrug, tenofovir disoproxil fumarate (TDF), to protect against transmission of human immunodeficiency virus (HIV) infection. Also disclosed are other nucleoside reverse transcriptase inhibitors (NRTIs) and nucleotide reverse transcriptase inhibitors (NtRTIs) that, when administered in combination, protect against HIV infection. CDC researchers demonstrated that daily pre-exposure prophylaxis (PrEP) with a combination of antiretroviral NRTI and NtTRI drugs, including FTC and TDF, significantly increases the level of protection against HIV transmission.
Commercial Applications
- Oral, prophylactic delivery of combination drugs to inhibit HIV infection
Request More Info
Licensing Contact: